Friday, 6 November 2015

West Coast experience of Alemtuzumab

Willis MD et al Alemtuzumab for multiple sclerosis: Long term follow-up in a multi-centre cohortMult Scler. 2015 Oct 29. pii: 1352458515614092. [Epub ahead of print]

BACKGROUND:Alemtuzumab has recently been approved for treatment of relapsing MS, but concerns remain about its use since long-term studies of adverse events remain limited. Furthermore, a clear understanding of its application and durability of effect in clinical practice has yet to evolve.
OBJECTIVES:To investigate long-term efficacy and safety outcomes in a multicentre cohort of patients treated with alemtuzumab.
METHODS:Patients treated from 2000 and followed-up at three regional centres were identified. Baseline and prospective data were obtained and validated by clinical record review.
RESULTS:One hundred patients were identified with a mean follow-up of 6.1 years (range 1-13). Forty patients were retreated with at least one further treatment cycle. Annualized relapse rates fell from 2.1 to 0.2 (p<0.0001) post-treatment and were sustained for up to eight years of follow-up. Mean change in EDSS score was +0.14. Forty-seven patients developed secondary autoimmunity.
CONCLUSION: Observed reduction in relapse rates reflected those reported in clinical trials, but we were unable to corroborate previous observations of disability reversal. 40% of patients required additional treatment cycles. Autoimmune adverse events were common, occurring at a higher rate than previously reported, but were largely predictable, and could be managed effectively within a rigorous monitoring regime.



So this is the real life data from the west of England and Wales and shows that after mean of 6 years 60% of people had not needed treatment for the past 5 years and relapses had substantial dropped.
The majority of patients (53%) underwent or were planned to complete the standard two cycles of treatment. 28% patients received three treatments, 11% four treatments and one patient five treatments. Seven patients received one treatment cycle only. Between two and five years, 27% of patients had been retreated, increasing to 51% and 58% at five to ten years and greater than ten years follow-up, respectively. A small number of patients were unresponsive to treatment and continued to experience frequent clinical relapses: four patients had 10 post treatment relapses and had a post treatment ARR of >1.


The EDSS level in this group did not get better in comparision to the people in Cambridge. This may because people were in active disease when they started Alemtuzumab and showed recover. However the lesson here if you are going down this route do not expect what has been lost to be recovered and what you are trying to do is stop the condition getting worse. So when should you start to save brain, the sooner the better. Mean baseline EDSS was 4.0. Mean change in EDSS from treatment baseline was +0.14.

The level of autoimmunity was much higher than the trials and came in at about 50% and this is similar to the longer term follow up. So this is an Achilles heel. If anti-CD20 comes along with similar efficacy and no autoimmunity it maybe bye bye CAMPATH  so this aspect needs to get sorted ASAP. 

Ten patients i.e 10% developed pre-malignant or malignant conditions during the period of follow-up.

Thirteen pregnancies were recorded in twelve women (18%). Two pregnancies resulted in miscarriage and one was terminated.


The result you want to know is this how many people became secondary progressive and the answer was twelve patients (12%) were considered to have developed secondary progressive disease a mean of 3.8 years after initial treatment. Were these the people who did not respond

CoI: ProfG Multiple.

18 comments:

  1. As an alem patient (9 years since first treatment) I see these results as impressive. I only had two treatments and have had no relapses - my diagnosis was "quite aggressive MS". People considering this treatment should know that most of the side effects are picked up by monitoring and are easily treatable - the only medicine iI take is thyroxine. It is much more preferable than the disabling relapses I was experiencing before treatment.

    ReplyDelete
    Replies
    1. But what to do if a patient like me has had autoimmune thyroiditis before getting MS?

      There should be more information on patients taking Alem who has had problems with their thyroid glands - which kind of new autoimmune diseases will they get?

      Delete
  2. Baseline EDSS of 4.0 seems quite high. I wonder what the results would be with a baseline of less than 2?

    ReplyDelete
  3. Thanks MD. Any data on the buzz word of the day: brain atrophy?

    ReplyDelete
    Replies
    1. I can't remember if there was imaging in the paper I dont have the paper to hand.

      Delete
  4. Is there any research with Alem and its effect on male fertility? You know since its a chemo drug.

    There is a lot of research with MS, DMTs and pregnancy but I hardly seen anything for us blokes.

    ReplyDelete
    Replies
    1. http://multiple-sclerosis-research.blogspot.com/2013/09/cd52-and-sperm.html

      Delete
    2. Thanks for the reply
      I must have missed this blog

      Delete
  5. Any details on malignancies? 10% is a huge number

    ReplyDelete
    Replies
    1. I think 5 were similar , possiblyy cervical but I don't have the paper to hand

      Delete
    2. Yes I'd also like to know about malignancies. I'm currently deciding between tecfidera and Lemtrada and this may tip the balance

      Delete
    3. If 1 in 3 of us are likely to get cancer, 10% seems low. The study needs to show age and lifestyle prior to onset of MS to get a true analysis. One thing is certain some of us will get cancer with or without treatment.

      Delete
    4. I'm currently deciding between tecfidera and Lemtrada

      We can only compare the data in the trials with similar follow up otherwise you are comparing apples with oranges. There is insufficient long term data with Tecfidera

      Delete
    5. Isn't the long term suppression of the immune system the thing that's risky in Lemtrada, while tec works in a different way? I genuinely don't know - only just diagnosed so very new to all of this and trying desperately to educate myself as quickly as possible!!

      Delete
    6. What worries me is 10% developed malignancies/pre malignancies over six years of follow up, which I think is probably a higher rate than one in three over the whole of life. I'm not so bothered about cervical cell changes and precancerous skin cell changes as these are easily detected and treated. I'm not even massively bothered about thyroid cancer as that is relatively treatable, what really scares me is potentially giving myself a higher chance of getting lymphoma or leukaemia.

      Delete
    7. Alem is used to treat lympoma and leukaemias

      Delete
    8. I saw this on the Lemtrada.com site: 'Receiving LEMTRADA may increase your chance of getting some kinds of cancers, including thyroid cancer, skin cancer (melanoma), and blood cancers called lymphoproliferative disorders and lymphoma' - it would be good to know whether any of these cancers were seen in this study, and how many of each. Does the paper go into detail?

      Delete
  6. Great to see more UK numbers coming out - thanks for sharing!

    ReplyDelete

Please note that all comments are moderated and any personal or marketing-related submissions will not be shown.